Mass spectrometry-based personalized drug therapy

Release time:2020-09-08

Impact Factor:9.011

DOI number:10.1002/mas.21620

Affiliation of Author(s):中南大学湘雅医院

Teaching and Research Group:临床药理研究所

Journal:Mass Spectrometry Reviews

Key Words:Personalized drug therapy; Mass spectrometry; Therapeutic drug monitoring (TDM); Pharmacogenomics (PGx); Pharmacomicrobiomics; Pharmacoepigenomics; Immunopeptidomics; Cancer immunotherapy; Precision medicine

Abstract:Personalized drug therapy aims to provide tailored treatment for individual patient. Mass spectrometry (MS) is revolutionarily involved in this area because MS is a rapid, customizable, cost-effective, and easy to be used high-throughput method with high sensitivity, specificity, and accuracy. It is driving the formation of a new field, MS-based personalized drug therapy, which currently mainly includes five subfields: therapeutic drug monitoring (TDM), pharmacogenomics (PGx), pharmacomicrobiomics, pharmacoepigenomics, and immunopeptidomics. Gas chromatography-MS (GC-MS) and liquid chromatography-MS (LC-MS) are considered as the gold standard for TDM, which can be used to optimize drug dosage. Matrix-assisted laser desorption ionization-time of flight-MS (MALDI-TOF-MS) significantly improves the capability of detecting biomacromolecule, and largely promotes the application of MS in PGx. It is becoming an indispensable tool for genotyping, which is used to discover and validate genetic biomarkers. In addition, MALDI-TOF-MS also plays important roles in identity of human microbiome whose diversity can explain interindividual differences of drug response. Pharmacoepigenetics is to study the role of epigenetic factors in individualized drug treatment. MS can be used to discover and validate pharmacoepigenetic markers (DNA methylation, histone modification, and noncoding RNA). For the emerging cancer immunotherapy, personalized cancer vaccine has effective immunotherapeutic activity in the clinic. MS-based immunopeptidomics can effectively discover and screen neoantigens. This article systematically reviewed MS-based personalized drug therapy in the above mentioned five subfields.

Co-author:Hong-Hao Zhou, Zhi-Rong Tan, Lei-Yun Wang

First Author:Jia-Jia Cui

Indexed by:Article

Correspondence Author:Ji-Ye Yin, Xianquan Zhan

Discipline:Medicine

First-Level Discipline:Pharmaceutical Science

Document Type:J

Volume:39

Issue:5-6

Page Number:523-552

ISSN No.:1098-2787

Translation or Not:no

Date of Publication:2020-01-05

Included Journals:SCI

Links to published journals:https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/mas.21620